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The AKT protooncogene mediates many cellular processes involved in normal development and disease states such as cancer. The
three structurally similar isoforms: AKT1, AKT2, and AKT3 exhibit both functional redundancy and isoform-speciﬁc functions;
however the basis for their diﬀerential signalling remains unclear. Here we show that in vitro, puriﬁed AKT3 is ∼47-fold more
active than AKT1 at phosphorylating peptide and protein substrates. Despite these marked variations in speciﬁc activity between
the individual isoforms, a comprehensive analysis of phosphorylation of validated AKT substrates indicated only subtle diﬀerences
in signalling via individual isoforms in vivo. Therefore, we hypothesise, at least in this model system, that relative tissue/cellular
abundance, rather than speciﬁc activity, plays the dominant role in determining AKT substrate speciﬁcity in situ.
1.Introduction
The AKT protooncogene comprises a family of three highly
homologous serine/threonine kinases (AKT1, 2 and 3) [1],
that play major regulatory roles in a wide range of cellu-
lar processes including cell survival, growth, proliferation,
angiogenesis, and metabolism [2–4] .T h e s ep r o c e s s e sa r ek e y
to normal development and often dysregulated in disease.
Consistent with these wide-ranging roles, to date, more than
100 AKT substrates have been identiﬁed that are integral in
the regulation of one or more of these cellular processes [3].
Each AKT isoform consists of a pleckstrin homology
domain (>75% identity), a linker region (>17% identity),
a kinase domain (>87% identity), and a carboxyl tail with
ah y d r o p h o b i cm o t i f( >66% identity) [1]. The two key
regulatory phosphorylation sites on AKT are also conserved,
Ser473 and Thr308 in AKT1, Ser474 and Thr308 in AKT2,
and Ser472 and Thr305 in AKT3 [5]. Thr308 is phospho-
rylated by 3-Phosphoinositide-dependent kinase 1 (PDK1)
and Ser473 by mammalian target of rapamycin (mTOR)
complex 2 (mTORC2) [6–9]. Recent studies have suggested
that phosphorylation at Ser473 dictates AKT signaling to
a speciﬁc set of substrates, and phosphorylation at Thr308
determines the kinase activity [8, 10].
Whilst all three AKT isoforms share a high sequence
identity and exhibit functional redundancy, there is also
genetic evidence that they can function distinctly. This is
illustrated in the distinct phenotypes exhibited by the single
isoform knockout (KO) mice and the severe phenotypes
e x h i b i t e db yd o u b l eK O( d K O )m i c e .A K T 1 −/− mice are not
100% viable, with surviving mice that reach adulthood being
15–20% smaller than their wild type (wt) and heterozygous
counterparts [11]. Furthermore, AKT1−/− mice exhibit a
smaller brain and liver as a result of a reduction in cell
number when compared to wt mice [12] indicating that
AKT1 is important in regulating proliferation. Heart size2 Enzyme Research
was also reduced; however it was caused by a decrease in
cell size [12], suggesting that AKT1 predominantly aﬀects
cell growth in this tissue. The AKT2−/− mice exhibited a
very diﬀerent phenotype, reminiscent of mice with Type 2
diabetes mellitus, suggesting a speciﬁc role for this isoform
in glucose metabolism [13] although more recent studies
in AKT1−/− mice have indicated that both AKT1 and 2 are
required for the regulation of glucose homeostasis in the
periphery [14]. AKT3−/− mice are not growth retarded but
show a 25% reduction in brain size due to decreased cell
number and a smaller cell size [12]. The phenotypes of AKT
dKO mice were more severe than that observed in single KO
mice. AKT1/2−/− mice die shortly after birth and suﬀer from
severe dwarﬁsm, impaired skin development, skeletal muscle
atrophy, impaired adipogenesis, and bone development [15],
none of which was observed for the individual KO mice.
The additive eﬀect of AKT1 and AKT2 suggests a func-
tional redundancy between these two isoforms. AKT1/3−/−
mice die between E11-E12, indicating the importance of
AKT1 and AKT3 in postnatal survival [16]. AKT2/3−/−
mice are viable but smaller than their wt counterparts
[17]. This less severe phenotype than the other compound
mutants indicates a dominant role for AKT1, at least in
development.
Recent studies suggest that the diﬀerent AKT isoforms
can signal via distinct subsets of downstream pathways and
that these subsets can vary depending on cellular and tissue
context [12], reinforcing the need to investigate isoform-
speciﬁc signaling in diﬀerent cell types. For example, AKT3
but not AKT1 is crucial for activation of the mTORC1/S6K1
signaling pathway in brain [12]. Furthermore, cellular
context has been seen to be important for AKT1 signaling
where AKT1−/− livers were smaller due to reduced cell
number while AKT1−/− hearts were smaller entirely because
of reduced cell size [12]. In addition, evidence for distinct
signaling pathways to and from individual AKT isoforms
is beginning to accumulate. For example, reduction of
PTEN expression in melanocytes activates AKT3 apparently
without aﬀecting the activity of AKT1 or 2 [18]. While
the mechanism for this selective activation remains to be
elucidated it provides an intriguing precedent.
Deﬁning the mechanism(s) of diﬀerential signaling via
these highly homologous AKT isoforms will be critical for
understanding the role played by AKT in many essential cel-
lular functions. It is clear that diﬀerential expression patterns
can explain some of these functional roles. AKT1 is widely
expressed in tissues including the brain, heart, lung, skeletal
muscle, thymus, and skin while AKT2 is predominantly
expressed in brown fat and the heart, and AKT3 was most
abundantly expressed in the brain [16]. Moreover, AKT
isoforms have been shown to localize to diﬀerent subcellular
compartments in a cell-line-speciﬁc manner [19, 20]. In
unstimulated cells, AKT1 localised in the cytoplasm, AKT2
at the mitochondria, and AKT3 in the nucleus of breast,
prostate, and liver cancer cell lines [20]. However, insulin-
stimulated adipocytes demonstrated a higher level of AKT2,
than AKT1, localization at the plasma membrane, thus
linking AKT2 to the isoform-speciﬁc regulation of GLUT4
translocation and glucose metabolism [19].
In addition to variation in expression and localization
patterns, diﬀerences in the intrinsic activity of the isoforms
in phosphorylating synthetic peptide substrates have been
reported [21–24]. Indeed, we have shown previously that
puriﬁed AKT isoforms vary with their speciﬁc activity in
phosphorylating model peptide substrates, with AKT3 being
∼15-fold more active than AKT1 which was ∼10-fold more
active than AKT2 [25]. These ﬁndings were consistent with
the ﬁndings of Walker et al. [24] who puriﬁed each isoform
from HEK293 cells and further activated them by incubation
with PDK1. In these experiments, a truncated form of AKT3
was 3-fold more active than AKT1 that was 5-fold more
active than AKT2 [24]. Here we have examined whether
these fundamental diﬀerences in enzyme kinetics contribute
to substrate speciﬁcity in vivo.
Given the cell-type-speciﬁc regulation of isoform-
dependent signaling described above, we chose to directly
compare the intrinsic activity of individual AKT isoforms
puriﬁed from HEK293 cells with their ability to phospho-
rylate in vivo substrates in the same cell type. HEK293
were chosen as they enable high levels of expression of
exogenous AKT to allow puriﬁcation of suﬃcient kinase
to enable detailed kinetic analysis of enzyme activity. We
focused our study on AKT 1 and 3 predominantly given
the low activity of AKT2 after conﬁrming this using
isoforms immunopuriﬁed from HEK293 cells stimulated
with serum, insulin, and pervanadate. We ﬁrst conﬁrmed
that AKT3 was indeed more active than AKT1 in pep-
tide kinase assays and against a newly identiﬁed protein
substrate, ribosomal protein S7 (rpS7) (see supplementary
Figure 1 in Supplementary Material available online at
dois 10.4061/2011/720985; [26]). We have used gain- and
loss-of-function approaches employing constitutively active
forms of the isoforms and speciﬁc siRNAs to examine
in vivo AKT isoform-speciﬁc signaling towards established
direct AKT substrates involved in cell proliferation, survival,
and growth including GSK3α/β, FoxO1/3a, MDM2, and
PRAS40, and via the activation of the mTORC1 pathway
leading to cell growth. In contrast to the marked diﬀerences
in intrinsic enzyme activity between the AKT isoforms,
only subtle diﬀerences in in vivo substrate speciﬁcity were
observed. This thus suggests that AKT isoform-speciﬁc
regulation of cellular function is, in a large part, dic-
tated by the relative expression levels in the relevant cell
type.
2.MaterialandMethods
2.1. Cell Culture and Treatments. Human embryonic kid-
ney (HEK293) cells were cultured in Dulbecco’s Modiﬁed
Essential Medium (DMEM) plus 10% (v/v) fetal bovine
serum (FBS) and 1% (v/v) antimycotic/antibiotic (Am/Ab,
Invitrogen) and maintained at 37◦Ci n5 %C O 2.C e l l sw e r e
serum-starved(DMEMnoFBS)for24hoursthenstimulated
with 1 μM insulin, 0.1μM pervanadate or 10% FBS for
20 minutes or pretreated with 5μM AKT inhibitor (AKTi,
Calbiochem, # 124017), 20nM rapamycin (Calbiochem,
#553210), or both for 30 minutes then stimulated with 10%
FBS for 20 minutes.Enzyme Research 3
2.2. Harvesting Cells for Protein Lysates. Proteins were harve-
sted as described in [25]. Brieﬂy, cells were lysed in Rac Lysis
Buﬀer (RLB: 50mM Tris-hydrochloride (Tris-HCl) pH7.5,
1% (v/v) NP-40, 120mM sodium chloride (NaCl), 1mM
ethylenediaminetetraaceticacid(EDTA),50mMsodiumﬂu-
oride,40mMβ-glycerophosphate,0.1mMsodiumvanadate,
1mM benzamidine, complete EDTA-free protease inhibitor
cocktail (Roche), and phosSToP phosphatase inhibitor cock-
tail (Roche)) and cleared by centrifuging (16000×g, 15
minutes, 4◦C). Samples were snap frozen and stored at
−80◦C. The protein concentration was determined using the
DC protein assay kit (BioRad).
2.3.ExpressionandPuriﬁcationofRecombinantAKTIsoforms.
HEK293 cells were transfected via the calcium phosphate
method [27] with pCDNA3 HA-tagged wtAKT1, wtAKT2,
or pCMV5 HA-tagged wtAKT3 (Pearson Laboratory),
pCDNA3 GST-wtAKT1 [28], pCMV5 GST-wtAKT3 [25],
or pCDNA3 constitutively active myristoylated (myr) HA-
tagged AKT1, AKT2, or AKT3 (Pearson Laboratory). Cells
were treated and harvested into RLB and lysates cleared
by centrifugation (14500×g, 15 minutes, 4◦C). HA-tagged
AKTisoformswereimmunoprecipitated fromclearedlysates
(100μg) using Protein A Sepharose 4B beads (Zymed). GST-
tagged AKT isoforms were puriﬁed by aﬃnity chromatogra-
phy as described in [28, 29]. Eluates were combined, buﬀer
exchanged by overnight dialysis against 0.27M sucrose in
RLB, and puriﬁed GST-tagged wtAKT concentrated using
C e n t r i c o n5 0 s( M i l l i p o r e ) ,s n a p p e df r o z e n ,a n ds t o r e da t
−80◦C. Samples were resolved by SDS-PAGE alongside
known concentrations of bovine serum albumin (BSA),
Coomassie R-250 stained, and the concentration determined
by densitometry using Scion Image software (Scion Incorpo-
ration).
2.4. Expression and Puriﬁcation of HIS-rpS7. Human ribo-
somal protein S7 (rpS7, gift from Dirk G¨ orlich, Heidelberg
[30]) was cloned into the pQE-60 vector using restriction
sites NcoI and BamHI and transformed into XL-Blue E.coli
cells. Expression of HIS-rpS7 was induced with 1mM
isopropyl-β-D-thio-galactoside (IPTG) for 5 hours, cells
pelleted (6000 ×g, 4◦C, 10 minutes), resuspended in buﬀer
A (300mM NaCl, 50mM sodium phosphate buﬀer, pH 7.0),
and sonicated. The insoluble fraction was pelleted as above,
resuspended in 20mL of buﬀer B (8 M urea in buﬀer A), and
sonicated. The clariﬁed sample was tumbled with talon resin
(Clontech) for 2 hours at room temperature (RT), washed
3t i m e sw i t hb u ﬀer B, and HIS-rpS7 eluted with 150mM
imidazole. HIS-rpS7 was dialysed sequentially for 4 hours
at 4◦C against: 4M urea in PBS−/−; 2M urea in PBS−/−,
20% glycerol and 0.5mM phenylmethylsulphonyl ﬂuoride
(PMSF); 0.5M urea in PBS−/−, 20% glycerol and 0.5 M
PMSF;andtwiceinPBS−/−,20%glyceroland0.5mMPMSF.
Puriﬁed HIS-rpS7 was clariﬁed by centrifugation (20000 ×g,
2m i n u t e s ,4 ◦C )a n ds t o r e da t−80◦C.
2.5. SDS-PAGE and Immunoblotting. Protein lysates (20–
50μg) were resolved by sodium dodecyl sulphate polyacry-
lamide gel electrophoresis (SDS-PAGE) alongside Bench-
mark Prestained Protein Ladder (Invitrogen) or PageRuler
Prestained Protein Ladder Plus (Fermentas). Proteins were
then transferred onto immobilon-P membrane (Millipore)
and immunoblotted with primary antibodies listed in Sup-
plementary Table 1. Antimouse and antirabbit horseradish
peroxidase-conjugated secondary antibodies (BioRad) were
used at 1:2000 dilution. Signals were detected by enhanced
chemiluminescence (Perkin Elmer) onto ﬁlm and quantiﬁed
by densitometry using ImageJ 1.42q (National Institutes of
Health, USA). Paired t-test statistical analysis was performed
using GraphPad Prism version 5.00, GraphPad Software, San
Diego, Calif, USA, http://www.graphpad.com/.
2.6. Coomassie R-250 Staining. After SDS-PAGE, gels were
stained with Coomassie R-250 (0.2% Coomassie R-250, 50%
ethanol,10%aceticacid)for1hourthendestainedwith25%
ethanol plus 7% acetic acid.
2.7. Knockdown of Endogenous AKT Isoforms. Individual
AKT isoforms were silenced using On-Target plus SMART-
pool smallinterfering RNAs(siRNAs) purchasedfromDhar-
macon (AKT1: L-003000-00, AKT2: L-003001-00, AKT3:
L-003002-00). Control siRNAs targeting enhanced green
ﬂuorescent protein (EGFP) were purchased from Sigma-
Proligo (siEGFP 5  sequence: 5 -GCAGCACGACUUCUU-
CAAGTT-3 , siEGFP 3  sequence: 5 -CUUGAAGAAGUC-
GUGCUGCTT-3 ). HEK293 cells at 50–60% conﬂuency
were transfected with 25nM of siAKT1, siAKT2, or siAKT3
either individually or simultaneously using lipofectamine
reagent (Invitrogen) following the manufacturer’s instruc-
tions. After 4 hours, the media was replaced with DMEM
plus 10% FBS and 1% Am/Ab then incubated overnight.
2.8.DirectKinaseAssay. Directkinaseassayswereperformed
as described in [31]. Brieﬂy, puriﬁed or immunoprecipitated
AKT were incubated with [γ-32P]ATP and varying concen-
trations of RPRAATF peptide or HIS-rpS7 at 30◦Cf o r2 0
minutes. The assay was terminated by spotting onto p81
paper,washed,dried,and[γ-32P]countedusingtheTri-Carb
2100TR liquid scintillation analyzer (Skudtek Scientiﬁc, Pty
Ltd). For whole cell lysates, the reaction was terminated by
adding 10μL of 10% trichloroacetic acid. The sample was
then cleared, spotted onto p81 paper, and counted as above.
InthecaseofHIS-rpS7,sampleswereresolvedbySDS-PAGE,
the gel stained with Coomassie R-250, dried, the appropriate
bands excised and counted as above.
2.9. Two Dimensional Gel Electrophoresis (2DGE). All chemi-
cals were purchased from GE Healthcare or Sigma. Protein
samples lysed in RLB were precipitated using the Ettan
2D Clean up Kit (GE Healthcare), resuspended in labelling
buﬀer (7M urea, 2M thiourea, 4% CHAPS, 30mM Tris)
and the protein concentration determined using the Ettan
2D Quant Kit (GE Healthcare). Protein samples (50μg) were
adjusted to pH 8.5 with 100mM sodium hydroxide, labelled
in the dark with 400pmol of CyDye Fluor minimal dye Cy2
(GE Healthcare) for 30 minutes on ice and then quenched4 Enzyme Research
with 10mM lysine. Labelled samples were combined with
unlabelled proteins to a total of 250μg, adjusted to a ﬁnal
volumeof340μL(7Murea,2Mthiourea,4%(w/v)CHAPS,
0.004% (w/v) bromophenol blue (BPB), 1% (w/v) DTT, and
1% (v/v) IPG buﬀer) and passively rehydrated onto an 18
cm,nonlinearpH3–11ImmobilineDryStripgel(GEHealth-
care). Proteins were focused using the Ettan IPGphor3 (GE
Healthcare) at 20◦Cw i t h5 0μA per strip using the following
protocol: step and hold at 150V for 3 hours, step and hold at
300V for 3 hours, gradient to 1000V for 6 hours, gradient to
10000V for 1 hour, step and hold at 10000V for 3 hours.
Immobiline DryStrip gels were incubated in equilibration
buﬀer (6M Urea, 2% (w/v) SDS, 50mM Tris·HCl pH
8.8, 0.002% BPB, 30% (v/v) glycerol) containing 1% (w/v)
DTT for 15 minutes, and then incubated in equilibration
buﬀer containing 2.5% (w/v) iodoacetamide for 15 minutes.
Proteins were resolved in a 12.5% gel at 0.5 W/gel for 1
hour, then 17 W/gel for 3 hours using the Ettan DALTsix
gel running tank (GE Healthcare). Gels were either stained
with Coomassie G-250 (10% (w/v) ammonium sulphate,
0.1% Coomassie (w/v) G-250, 3% (v/v) orthophosphoric
acid, 20% (v/v) ethanol) or transferred onto Hybond-LFP
(GE Healthcare) and immunoblotted with the Phospho-
AKT Substrate (PAS) antibody (Supplementary Table 1) and
Cy5conjugatedsecondaryantibody(GEHealthcare).Signals
were detected by scanning with the Typhoon tri9100 (GE
Healthcare). Total protein (Cy2) and PAS (Cy5) signals were
overlayed using ImageQuant (GE Healthcare). Protein spots
of interest were manually excised from the Coomassie G-250
stained gel and identiﬁed by mass spectrometry.
2.10. Mass Spectrometry. Protein samples are resolved by
SDS-PAGE,CoomassieR-250stainedandproteinsofinterest
excised, in-gel tryptic digested and identiﬁed using LC-ESI-
MS/MS using an Agilent 1100 Series HPLC coupled to an
Agilent LC/MSD Trap XCT Plus Mass Spectrometer ﬁtted
with an HPLC Chip cube (Agilent, Palo Alto, Calif). Mass
spectrometry was performed by the Core Facility at Peter
MacCallum Cancer Centre, utilising facilities at Bio21 RTF
(Parkville, VIC, Australia). The data acquired were analysed
by correlating the peptide masses obtained to predict peptide
masses from proteins in the NCBI nonredundant database
using the Mascot search engine (Matrix Science).
3. Results
3.1.RelativeSpeciﬁcActivityofAKTIsoforms. Previouslydata
from our laboratory using model peptide substrates revealed
that AKT3 was ∼15-fold more active than AKT1 which was
∼10-foldmoreactivethanAKT2[25].ToconﬁrmthatAKT2
was intrinsically considerably less active compared with
AKT1 and 3 when expressed in HEK293 cells, HA-tagged
versions of each isoform were immunopreciptated from
HEK293 cells stimulated with serum, insulin, or pervanadate
(Figures 1(a) and 1(b)). Under all conditions, AKT2 activity
was minimal, despite robust expression. Thus, we have
focused the present studies largely on AKT1 and 3.
To conﬁrm that this diﬀerence in relative enzyme activity
extended to the ability of the isoforms to phosphorylate
a protein substrate, expressed GST-tagged AKT1 and 3
isoforms were puriﬁed from pervanadate-treated HEK293
cells and the kinetics of phosphorylation of the RPRAATF
peptide [6, 31] compared to that with rpS7 protein. rpS7
has recently been identiﬁed as an in vivo substrate of the
AKT signaling network [26] ,a n dw eh a v ec o n ﬁ r m e dt h i sa s
a direct in vitro AKT substrate (Supplementary Figure 1).
GST-AKT3 was ∼47-fold more active than GST-AKT1
towards the RPRAATF peptide substrate, with their Vmax
values calculated as 315.90 ± 88.95nmol/min/mg and 6.73
± 0.69nmol/min/mg, respectively (Figures 1(c) and 1(d)).
GST-AKT3 was ∼5-fold more active than GST-AKT1
in phosphorylating rpS7 with a Vmax value of 12.67 ±
0.47nmol/min/mg and 2.27 ± 0.20nmol/min/mg, respec-
tively (Figure 1(e)). While the diﬀerences in speciﬁc activity
were marked, the fold change was considerably less with
the protein compared to the synthetic peptide substrate.
Furthermore, GST-AKT3 had a lower aﬃnity for the rpS7
protein than GST-AKT1, with Km values of 6.43 ± 0.62μM
and 1.24 ± 0.63μM, respectively. Thus, despite the markedly
higher Vmax for AKT3, its elevated activity will be dependent
on higher substrate concentrations than AKT1 meaning that
the local concentrations of speciﬁc substrates may be critical
in determining isoform-speciﬁc signaling.
3.2. Gain of Function Approach to Determine AKT Substrate-
Speciﬁc Phosphorylation. In order to examine the potential
outcomes of these diﬀerent intrinsic enzyme properties
on in vivo substrate phosphorylation, HA epitope tagged
forms of constitutively activated N-terminal myristoylated
(myr) AKT1, 2, and 3 were expressed in serum-starved
or stimulated HEK293 cells (panAKT western blot, Figures
2(a) and 2(b)). Transfection conditions were optimised
to achieve similar expression levels for each isoform as
indicated by the anti-HA western blot (Figures 2(a) and
2(c)). Analysis of AKT regulatory phosphorylation sites
revealed that enforced expression of each isoform resulted
in constitutive phosphorylation at Ser473 (Figures 2(a) and
2(d)). Thr308 phosphorylation was also markedly increased
in myrAKT1 and myrAKT3 transfected cells (Figures 2(a)
and 2(e)), consistent with elevated total AKT activity
compared with cells expressing myrAKT2. Direct kinase
assays conﬁrmed that myrAKT1 and 3 exhibit constitutive
activity (Figure 2(f)). To examine the in vivo eﬀects of
enforced expression of these speciﬁc isoforms, we took a
targeted substrate approach, focusing on known direct AKT
substrates involved in key cellular processes: proliferation
(GSK3αandGSK3β);survival(FoxO1,FoxO3aandMDM2);
growth (PRAS40) (Figure 3).
3.2.1. Eﬀect of Enforced AKT Isoform Expression on Prolifera-
tion:GSK3αandGSK3β. Glycogensynthasekinase3(GSK3)
is a negative regulator of cell proliferation [4, 32, 33]a n d
has been implicated in various diseases including diabetes,
alzheimer’s, and cancer [34]. GSK3 is expressed as two
isoforms, GSK3α and GSK3β, in similar tissues [35], and
their activity is inhibited by AKT which phosphorylates the
regulatory site Ser21 and Ser9, respectively [32, 36]. Overex-
pression of myrAKT1 and 3, but not myrAKT2, signiﬁcantlyEnzyme Research 5
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Figure 1: AKT3 is more active than AKT1 towards both the RPRAATF peptide and rpS7 protein substrate. HA-AKT isoforms were expressed in HEK293
cells, stimulated with 10% serum, 1μM insulin, or 0.1 μM pervanadate and harvested into RLB. (a) expression of HA-AKT isoforms was detected by
immunoblotting with the anti-HA antibody. (b) HA-AKT isoforms were immunoprecipitated from cleared protein lysates (100μg) and assayed towards
the RPRAATF peptide for activity. Samples were assayed in duplicate. n = 1–3. Error bars: mean ± SD. GST-AKT1 and GST-AKT3 were expressed in HEK293
cells, stimulated with 0.1μM pervanadate, and harvested into RLB, then puriﬁed by GST-pull down and (c and d) assayed against increasing concentrations
of the RPRAATF peptide or (e) rpS7. Data points were ﬁtted to the Michaelis-Menten equation using GraphPad Prism version 5.00, GraphPad Software, San
Diego, Calif, USA, http://www.graphpad.com/. n = 1, where samples were assayed in duplicate. Graph shows mean of duplicates.6 Enzyme Research
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Figure 2: Comparison of AKT isoform-speciﬁc activation in vivo and activity in vitro. HEK293 cells were transfected with the pCDNA3
vector (control) or myrAKT isoforms, serum-starved for 24 hours, then stimulated with 10% serum for 20 minutes. (a) protein lysates (20–
50μg) were separated by SDS-PAGE, transferred onto PVDF membrane, and immunoblotted. Western blots are representative of n = 1–5
experiments. Signals were quantiﬁed by densitometry using ImageJ 1.42 q (National Institutes of Health, USA), normalised to loading and
expressed as fold change over myrAKT1 serum-starved samples. (b) panAKT. n = 1 (c) HA-tag. (d) phospho-Ser473. (e) phospho-Thr308.
(c–e) Serum-starved samples: n = 4, stimulated samples: n = 1. Error bars: mean ± SD. (f) protein lysates (20μg) were incubated with the
RPRAATF peptide substrate in the presence of [γ-32P]ATP at 30◦C for 20 minutes to determine total AKT activity. Each sample was assayed
in duplicate. Levels of AKT activity are represented as fold change over the serum-starved control sample. n = 2–6, Graph shows mean ±
S.D. Statistical analysis was performed using the paired t-test (GraphPad Prism version 5.0, GraphPad Software, San Diego, Calif, USA).
Paired t-test was not calculated between serum-starved control and myrAKT1 for (c and e) as the fold diﬀerence was the same for all blots
quantiﬁed. P values >0.05 are not signiﬁcant, P values 0.01 to 0.05 (∗), P values 0.001 to 0.01 (∗∗), and P values <0.001 (∗∗∗).
increased GSK3α (Ser21) phosphorylation under serum-
starved conditions (Figures 3(a)(i), and 3(b)). However, all
three myrAKT isoforms signiﬁcantly increased GSK3 (Ser9)
phosphorylation under serum-starved conditions (Figures
3(a)(i), and 3(c)), suggesting that AKT2 speciﬁcally targeted
GSK3β over GSK3α despite its apparent extremely low
peptide phosphorylating activity. The data presented here
suggests that constitutive AKT1 and 3 but not AKT2 activity
are suﬃcient to phosphorylate GSK3α, while all three
isoforms are suﬃcient in phosphorylating GSK3β.
3.2.2. Eﬀect of Enforced AKT Isoform Expression on Survival:
FoxO1, FoxO3, and MDM2. One mechanism by which AKT
modulates cell survival involves phosphorylation and thus
inactivation of the FoxO family of transcription factors
which regulate the expression of various genes associated
with apoptosis, the cell cycle, and DNA repair [37]. AKT
directly phosphorylates FoxO1 at residues Thr24 and Ser256,
and FoxO3a at Thr32 [37–40], however, other kinases are
also capable of FoxO protein phosphorylation [37–40].
In this study, FoxO1 (Thr24) and FoxO3a (Thr32) were
robustly phosphorylated in response to serum (Figure 3(a)
(iii)). In serum-starved conditions, the overexpression of all
three constitutively active AKT isoforms (Figures 3(a)(iii),
and 3(d)) modestly increased FoxO1/3a (Thr24/32) phos-
phorylation with myrAKT1 and 3 being more potent than
myrAKT2. This suggests that all isoforms are suﬃcient to
phosphorylate FoxO1/3a at residues Thr24 and 32, respec-
tively. However, in all three cases this was not additive with
serum treatment (Figure 3(a)(iii)) indicating that serum
stimulation causes maximal phosphorylation at these sites.
Interestingly, none of the constitutively active myrAKT
isoforms was suﬃcient to induce FoxO1 (Ser256) phospho-
rylation in serum-starved conditions (Figures 3(a)(iv), and
3(e)). Indeed, serum induced phosphorylation of FoxO1 at
Ser256trendedloweruponexpressionofconstitutivelyactive
AKT isoforms.
AKT also regulates cell survival by phosphorylating
murine double minute 2 (MDM2) at residue Ser166, which
results in its translocation into the nucleus and binding to
p53, a tumour suppressor that acts as a transcription factor
to express proapoptotic genes. The p53/MDM2 complex is
then sequestered to the cytoplasm for proteasomal degra-
dation [4, 41, 42]. Overexpression of all myrAKT isoforms
was suﬃcient to induce phosphorylation under serum-
starved conditions (Figure 3(a)(v), top band indicated by
arrow), thus suggesting that all isoforms are suﬃcient to
phosphorylate MDM2 at Ser166. However, this phospho-
rylation was not additive with serum when compared to
the control. The diﬀerences in the signal to noise between
individual western blots made statistical analysis of MDM2
phosphorylation from multiple gels impractical. However,8 Enzyme Research
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Figure 3: Continued.Enzyme Research 9
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Figure 3: Diﬀerential isoform-speciﬁc signaling to direct AKT substrates in vivo. (a) Protein lysates (20–50μg) generated from HEK293 cells
transfected with the pCDNA3 vector (control), or overexpressing HA-tagged myrAKT isoforms were resolved by SDS-PAGE, transferred
onto membrane, and immunoblotted. Western blots are representative of n = 2–5 experiments. Signals from serum-starved samples were
quantiﬁed by densitometry using ImageJ 1.42q (National Institutes of Health, USA), normalised to loading, and expressed as fold change
over myrAKT1 serum-starved samples. (b) phospho-GSK3α (Ser21). n = 5. Error bars: mean ± SEM. (c) phospho-GSK3β(Ser9). n = 5.
Error bars: mean ± SEM. (d) phospho-FoxO1/3a (Thr24/32). n = 5. Error bars: mean ± SEM. (e) phospho-FoxO1 (Ser256). N = 5. Error
bars: mean ± SEM. (f) phosph-PRAS40 (Thr246). n = 2. Error bars: mean ± SD. Statistical analysis was performed using the paired t-test
(GraphPad Prism version 5.0, GraphPad Software, San Diego, Calif, USA). Paired t-test was not calculated between serum-starved control
and myrAKT1 for (d) as the fold diﬀerence was the same for all blots quantiﬁed. P values >0.05 are not signiﬁcant, P values 0.01 to 0.05 (∗),
P values 0.001 to 0.01 (∗∗), and P values < 0.001 (∗∗∗).
as consistent trends were observed, a representative blot is
presented.
3.2.3. Eﬀect of Enforced AKT Isoform Expression on Growth:
PRAS40. AKT signals to mTORC1 via two converging
pathways to regulate cell growth. One pathway involves the
prolinerichAKTsubstrateof40kDa(PRAS40)andtheother
the tuberous sclerosis complex 2 (TSC2) [43–45]. Speciﬁ-
cally, PRAS40 inhibits Ras homolog enriched brain-(Rheb)-
dependent mTORC1 activity by binding to the raptor
subunitofmTORC1,andthisisrelieveduponitsphosphory-
lation at Thr246 by AKT [46]. Overexpression of each of the
constitutivelyactiveAKTisoformsresultedinrobustPRAS40
(Thr246)phosphorylationinserum-starvedconditions(Fig-
ures 3(a)(vi), and 3(f)). As observed for FoxO1/3a, this
phosphorylation was not additive upon serum stimulation,
nor was any diﬀerential isoform speciﬁcity observed.
3.3. Eﬀect of Enforced AKT Signaling down the mTORC1
Pathway. AKT is known to mediate cell growth by signaling
through the mTORC1 pathway primarily due to mTORC1
phosphorylation of initiation factor 4E-Binding Protein 1
(4E-BP1) and activation of S6 Kinase 1 (S6K1) that phos-
phorylates ribosomal protein S6 (rpS6) [47]. mTORC1 also
activates rDNA transcription [48]. These signals converge
to promote ribosomal biogenesis and function [49]. Thus
in this study 4E-BP1 and rpS6 were used as readouts of
AKTsignalingdownthemTORC1-growthsignalingpathway
(Figure 4).
3.3.1. Eﬀect of Enforced AKT Isoform Expression on 4E-
BP1. The function and activity of 4E-BP1 is modulated
by phosphorylation at multiple residues [50]. The 4E-
BP1 residues Thr37 and Thr46 are priming sites that
require phosphorylation by mTORC1 before other key
residues are available to kinases such as ERK2 and JNK
[50, 51]. In serum-starved conditions overexpression of all
myrAKT isoforms modestly increased 4E-BP1 (Thr37/46)
phosphorylation when compared to control (Figure 4(a)(i)).
Again, this phosphorylation was not additive upon serum
stimulation, nor was any diﬀerential isoform speciﬁcity
observed. As for MDM2, the diﬀerences in the signal to noise
between individual western blots made statistical analysis
of 4E-BP1 (Thr37/46) phosphorylation from multiple gels
impractical. However, as consistent trends were observed, a
representative blot is presented.
3.3.2. Eﬀect of Enforced AKT Isoform Expression on Ribosomal
Protein S6. ActivationofthemTORC1/S6K1 pathwayresults
in the phosphorylation of rpS6 at Ser235, Ser236, Ser240,
and Ser244 [52, 53]. In serum-starved cells, overexpression
of all three myrAKT isoforms increased rpS6 Ser235/236 and
Ser240/244 phosphorylation when compared to the control
(Figures 4(a)(ii)(iii), 4(b) and 4(c)), although this was con-
siderably less than the phosphorylation observed in response
to serum stimulation. Like 4E-BP1, no further elevation
in rpS6 Ser235/236 and Ser240/244 phosphorylation was
observed upon serum stimulation.
In conclusion, these experiments reveal that despite the
enforced expression of AKT isoforms with very diﬀerent10 Enzyme Research
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Figure 4: Expression of all three AKT isoforms is suﬃcient for signaling down the mTORC1 pathway. (a) Protein lysates (20–25μg)
generated from HEK293 cells transfected with the pCDNA3 vector (control), or overexpressing HA-tagged myrAKT isoforms were resolved
by SDS-PAGE, transferred onto membrane, and immunoblotted. Western blots are representative of n = 1 − 5 experiments. Signals from
serum-starved samples were quantiﬁed by densitometry and normalised to loading and expressed as fold change over myrAKT1 serum-
starved samples. (b) phospho-rpS6 (Ser235/236). n = 1. (c) phospho-rpS6 (240/244). n = 5. Error bars: mean ± SEM. Statistical analysis
was performed using the paired t-test (GraphPad Prism version 5.0, GraphPad Software, San Diego, Calif, USA). P values >0.05 are not
signiﬁcant, P values 0.01 to 0.05 (∗), P values 0.001 to 0.01 (∗∗), and P values < 0.001 (∗∗∗).
intrinsic kinase activities towards deﬁned peptide and
protein substrate, the resulting in vivo phosphorylation
patterns of known substrates is largely isoform independent.
Some subtle diﬀerences were identiﬁed including the lack
of phosphorylation of GSK3α by myrAKT2 and its reduced
phosphorylation of FoxO1/3a (Thr24/32).
3.4. Loss of Function Approaches to Determine AKT Sub-
strate Speciﬁc Phosphorylation. To further assess potential
diﬀerences in the requirement for speciﬁc isoforms for
substrate phosphorylation we used siRNA approaches to
knockdown the expression of each isoform individually and
in combination (Figures 5 and 6). Western blot analysis
using isoform-speciﬁc antibodies showed that the siRNAs
used speciﬁcally targeted their respective AKT isoform
(Figure 5(a)). Moreover, panAKT western blot analysis indi-
catedthatofthethreeisoforms,theindividualknockdownof
AKT1andAKT3mostrobustlyreducedtotalAKTexpression
(Figures 5(a) and 5(b)), thus suggesting that these two
isoforms may be more abundantly expressed in HEK293
cells. Moreover, when both AKT1 and AKT3 expression
were reduced, an additive reduction in endogenous AKT
expression was demonstrated (Figures 5(a) and 5(b)).
The contribution of each AKT isoform to total AKT
activity in vivo was also analysed by examining the levels
of phosphorylation at the two regulatory residues Ser473
and Thr308 (Figures 5(c)–5(e)). It should be noted that
combined knockdown of all isoforms did not fully ablate
AKT expression or phosphorylation but did reduce the levels
ofactivekinasetoasimilarleveltotheAKTinhibitor(AKTi),
which we have shown to inhibit all AKT isoforms in HEK293
cells when used at 5 μM (Chan et al. [54]).
As with the overexpression studies we took a targeted
approach focusing on AKT substrates involved in key cel-
lular processes: proliferation (GSK3α and GSK3β); survival
(FoxO1, FoxO3a and MDM2); growth (PRAS40). However,
manydirectAKTsubstratesarealsophosphorylatedbyother
kinases; for example, GSK3β and MDM2 are also substratesEnzyme Research 11
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Figure 5: Speciﬁc knockdown of endogenous AKT isoforms. HEK293 cells were serum-starved for 24 hours and pretreated with either
5μM AKTi, 20nM rapamycin, or both for 30 minutes prior to stimulation with 10% serum for 20 minutes and harvesting into RLB.
Endogenous AKT expression was knocked down, either individually or simultaneously, with 25nM of siRNAs towards speciﬁc AKT
isoforms and harvested into RLB. siEGFP was used as the control. Protein lysates (20–25μg) were separated by SDS-PAGE, transferred
onto PVDF membrane, and immunoblotted. Western blots are representative of n = 3 experiments. Western blot signals were quantiﬁed
by densitometry, normalised to loading and expressed as fold change over the serum-stimulated control. (a) Speciﬁcity of isoform-speciﬁc
knockdown and their eﬀects on total AKT expression were analysed by immunoblotting with isoform-speciﬁc and panAKT antibodies. (b)
panAKT. n = 3. Error bars: mean ± SEM. (c) Total AKT activation levels were analysed by immunoblotting with phospho-Ser473 and
phospho-Thr308 antibodies. (d) Phospho-Ser473. n = 3. Error bars: mean ± SEM. (e) Phospho-Thr308. n = 2, Error bars: mean ± SD.12 Enzyme Research
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Figure 6: Dependence of AKT isoform-speciﬁc expression for signaling down cell proliferation, survival, and growth pathways. (a) HEK293
cells were serum-starved for 24 hours before pretreatment with 5μM AKTi, 20nM rapamycin or both for 30 minutes prior to stimulation
with 10% serum and harvested into RLB. Expression of endogenous AKT isoforms were knocked down in HEK293 cells, either individually
or simultaneously, with 25nM of siRNAs towards speciﬁc AKT isoforms and harvested into RLB. siEGFP was used as the control. Protein
lysates (20–25μg) were separated by SDS-PAGE, transferred onto PVDF membrane, and immunoblotted. Western blots are representative
of n = 3 experiments. Intensity of western blot signals were quantiﬁed by densitometry, normalised to loading, and expressed as fold change
over the serum-stimulated control. (b) phospho-FoxO1/3a (Thr24/32). n = 2. Error bars: mean ± SD. (c) phospho-PRAS40 (Thr246).
n = 2. Error bars: mean ± SD.
of S6K1, a downstream kinase of mTORC1 [55, 56]. Thus,
to delineate direct AKT substrates from mTORC1-mediated
signaling, cells were treated with speciﬁc inhibitors of AKT
(AKTi) and/or mTORC1 (rapamycin) (Figure 6).
3.4.1. Eﬀect of AKT Isoform Knockdown on Proliferation:
GSK3α and GSK3β. Speciﬁc reduction in AKT isoform
expression individually or in combination did not modulate
thelevelofphosphorylatedortotalGSK3α(Ser21)orGSK3β
(Ser9) (Figure 6(a)(i)–(iii)). In fact, complete inhibition of
AKT activity with AKTi only marginally reduced GSK3
phosphorylation (Figure 6(a)(i)) despite the results showing
their dependence on AKT expression in the overexpression
studies (Figure 3(a)(i)). This may be due to other kinases
such as PKA and S6K1 that have been shown to also play an
active role in GSK3α (Ser21) and GSK3 (Ser9) phosphory-
lation [57]. In summary, under the conditions tested, AKT
is suﬃcient but not necessary for phosphorylation of GSK3α
(Ser21) and GSK3 (Ser9).
3.4.2. Eﬀect of AKT Isoform Knockdown on Survival:
FoxO1, FoxO3, and MDM2. Phosphorylation of FoxO1/3a
(Thr24/32) was markedly reduced upon knockdown of each
of the three AKT isoforms with AKT1 and 3 being moreEnzyme Research 13
potent than AKT2 (Figures 6(a)(iv), and 6(b)). This is
consistent with overexpression studies where myrAKT1 and
3 were shown to phosphorylate FoxO1/3a (Thr24/32) more
intensely (Figures 3(a)(iii), and 3(d)). Moreover, an additive
reduction in FoxO1/3a (Thr24/32) phosphorylation was
demonstrated upon the knockdown in expression of all three
AKT isoforms (Figures 6(a)(iv), and 6(b)). When combined
with the AKT overexpression studies we conclude that all
AKT isoforms are both suﬃcient and necessary for the phos-
phorylation of FoxO1/3a at Thr24 and Thr32, respectively.
In contrast knockdown of all AKT isoforms together had no
eﬀect on FoxO1 at Ser256 (Figure 6(a)(v)). This is consistent
with the data of Brognard et al. [58] who also failed to
observe altered FoxO1 (Ser256) phosphorylation upon the
knockdown of AKT isoform-speciﬁc expression in H157
cells, a non-small-cell lung cancer cell line. Additionally,
treatment with AKTi did not alter FoxO1 phosphorylation
at Ser256 (Figure 6(a)(v)). This is consistent with the lack
of eﬀect of overexpressing AKT on this substrate (Figures
3(a)(iv), and 3(e)). Taken together, these results suggest
that in HEK293 cells, AKT may mediate cell survival by
phosphorylating FoxO1/3a at Thr24/32 but not Ser256.
Phosphorylation of MDM2 (Ser166) was not altered
upon the individual or compound knockdown of the AKT
isoforms (Figure 6(a)(vi)). This suggests that AKT expres-
sion is not necessary for MDM2 Ser166 phosphorylation,
despite overexpression of AKT being suﬃcient to increase its
phosphorylation (Figure 3(a)(v)). Moreover, MDM2 phos-
phorylation at Ser166 was not reduced upon treatment with
AKTi (Figure 6(a)(vi)). This is in contrast to treatment with
the mTORC1 inhibitor rapamycin, which had a dramatic
eﬀectonMDM2(Ser166)phosphorylation(Figure 6(a)(vi)).
This suggests that under these conditions, AKT does not
regulate MDM2 (Ser166) phosphorylation while mTORC1
does and that mTORC1 must be activated in an AKT-
independent manner [59–61].
3.4.3. Eﬀect of AKT Isoform Knockdown on Growth: PRAS40.
Phosphorylation of PRAS40 (Thr246) was not signiﬁcantly
modulated by knockdown of any individual AKT isoform
(Figures 6(a)(vii), and 6(c)) although there was a subtle
reduction when RNAi to all three AKT isoforms were
combined. Moreover, AKTi treatment, but not rapamycin,
reduced PRAS40 (Thr246) phosphorylation (Figures
6(a)(vii), and 6(c)). In combination with the above data
this would suggest that AKT is both suﬃcient and necessary
for PRAS40 (Thr246) phosphorylation; however the AKT
isoformsarefunctionallycomplementarywithrespecttothis
substrate, with knockdown of all giving additive inhibition.
3.4.4. Eﬀect of AKT Isoform Knockdown on mTORC1 Signal-
ing Pathway. Consistent with the modest increase in 4E-BP1
(Thr37/46) phosphorylation induced by all constitutively
active AKT isoforms (Figure 4(a)), knockdown of each
individual AKT isoform reduced 4E-BP1 phosphorylation
as evidenced by disappearance of the lowest mobility
species (Figure 7(a)(i), indicated by an arrow). Furthermore,
phosphorylation of the Ser235/236 site on rpS6 (Figures
7(a)(ii), and 7(b)) was also reduced upon knockdown of
each individual AKT isoform. In contrast, reduction of
phosphorylation of Ser240/244 in rpS6 required knockdown
ofAKT1andwasoptimalwithallthree(Figures7(a)(iii),and
7(c)) raising the possibility that AKT1 exhibits some nonre-
dundant signaling to rpS6 phosphorylation. Interestingly for
both of these substrates all three of these phosphorylation
sites were robustly reduced with either AKTi treatment
or rapamycin (Figure 7(a)(i–iii)), consistent with the
importance of AKT in the regulation of mTORC1 function
which functions upstream of both 4E-BP1 and rpS6.
3.5. Diﬀerences in Signaling between AKT Isoforms Are Subtle
In Vivo. These data demonstrate dramatic diﬀerences in
peptide kinetics for the three AKT isoforms, which were less
markedwhenusingaproteinsubstrateinvitro(Figures1(c)–
1(e)). However regulation of the level of phosphorylation for
some known in vivo substrates, whether by overexpression
or speciﬁc knockdown of individual AKT isoforms, was
e x t r e m e l ys u b t l e .O n l yG S K 3 α (Ser21) and FoxO1/3a
(Thr24/32) exhibited clear diﬀerential regulation by the
AKT isoforms. Thus we took a third approach, to identify
potential AKT isoform-speciﬁc substrates by performing
an unbiased screen on cells overexpressing myrAKT1 or
myrAKT3 and utilizing 2DGE combined with western blot
analysis with the phospho-AKT substrate (PAS) antibody
that detects phosphorylation at AKT-speciﬁc motifs [62].
Consistent with our studies of validated substrates, the
patterns of phosphorylation of more than 30 AKT regulated
PAS signals were similar (Figure 8). However, some
diﬀerences were also observed. A group of proteins were
f o u n dt ob em o r ee ﬃciently phosphorylated by myrAKT1
compared to myrAKT3 (Figures 8(c) and 8(d), white circle)
while 5 phosphoproteins 4 of which were seemingly related,
were more eﬃciently phosphorylated by myrAKT3 than
myrAKT1 (Figures 8(c) and 8(d), black circle). Of the 5
spots more eﬃciently phosphorylated by myrAKT3, four
overlapped with Coomassie G-250 stained spots (Supple-
mentary Figure 2(c)), and these were excised, digested, and
subjected to mass spectrometry analysis. All four spots were
identiﬁedaseukaryotictranslationelongationfactor2(eEF2,
Supplementary Figure 3). The potential and signiﬁcance of
AKT mediated regulation of eEF2 remains to be elucidated.
Thus, in general the patterns of phosphorylation observed
using the 2DGE approach were similar for the two AKT
isoforms, although some subtle isoform-speciﬁc diﬀerences
were observed, consistent with the ﬁndings obtained
above for GSK3 and FoxO1/3a phosphorylation (Figure 3).
Thus, while relative expression levels are likely to underlie
the major isoform-speciﬁc signaling observed at least in
HEK293 cells, diﬀerences in intrinsic enzyme activity may
contribute to subtle modiﬁcations of the diﬀerential eﬀects
of AKT on the regulation of a range of cellular processes.
4. Discussion
AKT consists of a family of three homologous isoforms,
AKT1, 2, and 3, whose role in maintaining cellular home-
ostasis is thought to be pivotal in regulating processes14 Enzyme Research
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Figure 7: Eﬀect of AKT expression on activation of the mTORC1 pathway. (a) HEK293 cells were serum-starved for 24 hours before
treatment with 5μM AKTi, 20nM rapamycin or both for 30 minutes prior to stimulation with 10% FBS and harvested into RLB. Expression
of endogenous AKT isoforms were knocked down in HEK293 cells, either individually or simultaneously, with 25nM of siRNAs towards
speciﬁc AKT isoforms, and harvested into RLB. siEGFP was used as the control. Protein lysates (20–25μg) were separated by SDS-PAGE,
transferred onto PVDF membrane, and immunoblotted. The arrow indicates the hyperphosphorylated band of phospho-4E-BP1. Western
blots are representative of n = 3 experiments. Intensity of western blot signals was quantiﬁed by densitometry, normalised to loading and
expressed as fold change over the serum-stimulated control. (b) Phospho-rpS6 (Ser235/236). n = 2. Error bars: mean ± SD. (c) Phospho-
rpS6 (Ser240/244). n = 3. Error bars: mean ± SEM.
such as cell survival, growth, proliferation, angiogenesis,
and metabolism [3]. While much is known about the
complex regulation of this pathway, many questions remain
unanswered. Though the substrates that mediate some of
its pleiotropic eﬀects have been characterised, many critical
substrates remain to be identiﬁed [3]. Furthermore, studies
involving single and double knockout mice suggest that the
AKT isoforms may diﬀerentially signal to produce distinct
phenotypes [11–17, 63–65] .T h eb a s i so ft h i sd i ﬀerential
signaling and its impact on determining the roles of the
individual isoforms in regulating speciﬁc cellular functions
remain unclear.
Recently, potential AKT isoform-speciﬁc substrates have
come to light, providing one clear mechanism for diﬀerential
signaling; using loss-of-function studies, Brognard et al. [58]
showed that TSC2 (Ser939 and Thr1462) phosphorylation
was dependent on AKT1 and AKT2, but not AKT3, expres-
sion. Moreover, they showed that p27 (Thr157) phospho-
rylation was speciﬁcally dependent on AKT3 expression.
Additionally GSK3α (Ser21) and MDM2 (Ser166) phospho-
rylation was shown to be exclusively dependent on AKT2
expression.
Herewehaveaddressedthequestionofwhetherisoform-
speciﬁc signaling was due to diﬀerences in the intrinsic
activity of the isoforms. Previous reports have shown that
AKT3 is the most active isoform towards a range of peptide
substrates [21, 24, 25]. We conﬁrmed that AKT3 had the
highest speciﬁc activity compared to AKT1 and AKT2,
phosphorylating the RPRAATF synthetic peptide with∼47-
times the speciﬁc activity of AKT1. Importantly, we showed
that this hierarchy of activity was conserved for a protein
substrate (rpS7), but the diﬀerence in activity was reduced to
5-fold. These data indicated that the diﬀerences in intrinsic
kinase activity towards protein substrates may be moreEnzyme Research 15
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Figure 8: Identiﬁcation of eEF2 as a potential AKT substrate.
HEK293 cells transfected with the pCDNA3 vector (control) or
expressing similar levels of myrAKT1 or myrAKT3 were serum-
starved for 24 hours prior to harvesting into RLB. Samples were
processed in duplicate. Cy2 labelled protein samples (250μg)
were loaded onto 18cm broad range IPG strips with a nonlinear
pH range of 3–11, focused and resolved by SDS-PAGE. After
2DGE, gels were transferred onto Hybond-LFP membrane and
then immunoblotted with the PAS antibody and Cy5-conjugated
secondary antibody. Membranes were scanned using the Typhoon
trio9100 for both Cy2 and Cy5 signals. Cy2 and Cy5 signals
were overlayed using ImageQuant (GE Healthcare). Cy2 (total
protein) signals are represented in red. Cy5 (PAS) signals are
represented in green. Overlayed signals are represented in yellow.
(a) control. (b–d) enlarged region of membrane containing
control, myrAKT1 or myrAKT3 samples, respectively. Proteins
more eﬃciently phosphorylated by myrAKT1 are circled in white,
bymyrAKT3arecircledinblack,andwithequaleﬃcienciesforboth
are circled in blue. The four protein spots (spots 1–4) were excised
from the myrAKT1 Coomassie R-250 stained gel (Supplementary
Figure 2) and identiﬁed as eEF2 by mass spectrometry analysis
(Supplementary Figure 3). n = 1.
modest than ﬁrst thought and potentially of less impact in
vivo. Indeed, this concept is reinforced by the observation
that AKT3 had a 5-fold lower aﬃnity than AKT1 towards
the rpS7 protein meaning at limiting substrate concentra-
tions, the activity of the isoforms may be very similar.
Similar diﬀerences in the Km for peptide phosphorylation
were observed previously [25]. Alternatively, it is possible
that colocalization of AKT3 with important substrates will
facilitate local concentrations required for maximum AKT3
activity and provide a measure for isoform-speciﬁc signaling
not evident in the cytoplasm. Such sites may include the
translational apparatus or the nucleolus where ribosomal
proteins,suchasrpS7andribosomalRNAareassembledinto
ribosomes. Supporting this hypothesis is the recent ﬁnding
that AKT3 localises to the nucleus in a range of cell lines
including HEK293 [20].
To further examine the potential for isoform-speciﬁc
phosphorylation of substrates in vivo we determined the
eﬀect of enforced expression of constitutively active iso-
forms on the phosphorylation of key validated substrates,
GSK3α and GSK3β, FoxO1/3a, MDM2, and PRAS40. These
observations were complemented by loss-of-function studies
using isoform-speciﬁc siRNA reagents. Regulation of the
level of phosphorylation of these in vivo substrates, whether
by overexpression or speciﬁc knockdown of individual
AKT isoforms, was extremely subtle, indicating that rel-
ative expression levels are likely to underlie the major
isoform-speciﬁc signaling observed at least in HEK293
cells. Expression of each AKT isoform contributed to the
phosphorylation of FoxO1 at residue Thr24, but not at
Ser256 (Figure 6(a)(iv)(v), and 3(d) and 3(e)) consistent
with previous ﬁndings in H157, a non-small-cell lung cancer
cell line [58]. In addition, we showed isoform-speciﬁc
diﬀerences in the phosphorylation of FoxO1/3a (Thr24/32).
Overexpression of myrAKT1 and 3 resulted in a greater level
ofFoxO1/3a (Thr24/32) phosphorylation whencomparedto
myrAKT2 (Figure 3(a)(iii), and 3(d)). Consistent with these
ﬁndings, the knockdown of AKT1 and AKT3 expression
individually reduced the level of FoxO1/3a (Thr24/32) to
a greater extent than AKT2 (Figure 6(a)(iv), and 6(b)).
This indicates that the isoforms might vary in the strength
or eﬃciency to phosphorylate FoxO1/3a (Thr24/32), thus
resulting in diﬀerent abilities to regulate cell survival and
proliferation.
Takentogether,thesedataindicatethatdespiteexhibiting
very diﬀerent intrinsic enzyme activity, in vivo phosphory-
lation patterns induced by the activation of speciﬁc AKT
isoforms are very similar when expressed at similar levels
in a given cell type. These ﬁndings imply that diﬀerential
expression, activation, or localization of the isoforms may
play more dominant roles in determining isoform-speciﬁc
functions. However, diﬀerences in intrinsic enzyme activity
may contribute to subtle modiﬁcations of the diﬀerential
eﬀects of AKT on the regulation of a range of cellular pro-
cesses, including glucose metabolism and cell proliferation
(via GSK3) and cell survival (via FoxO1/3a). It is important
to note that the basis of isoform-speciﬁc signaling is likely to
vary depending on the type of cell or tissue. Certainly, recent
studies suggest that the substrates targeted by diﬀerent AKT16 Enzyme Research
isoforms can vary depending on cellular and tissue context
[12].
AKT isoforms have been shown to localise to diﬀerent
subcellular compartments in a cell-line-speciﬁc manner as
described above [19, 20]. It remains possible that overex-
pression of individual isoforms may subvert signal speciﬁcity
bychanging/overwhelmingthespeciﬁcityofAKTsubcellular
localization. Moreover, the AKT isoforms are expressed in
various tissues at diﬀerent levels. AKT1 is ubiquitously
expressed, while AKT2 is predominantly expressed in brown
fat and the heart [16], correlating with the role of AKT2
in diabetes and glucose metabolism. AKT3 was most abun-
dantly expressed in the brain [16] correlating with its role in
attaining normal brain size. Furthermore, there is growing
evidence that the diﬀerential expression of speciﬁc AKT
isoforms is associated with individual tumour types. AKT1
activity is frequently elevated in breast and prostate cancers
[66] while AKT2 has been shown to be upregulated in
pancreatic and ovarian carcinomas [67, 68]. We have shown
that AKT3 is upregulated in 20% of ovarian cancers [25].
Thus, it is also possible that, while our results reveal only
subtle diﬀerences in isoform-speciﬁc signaling in epithelial
cells, this may vary in other cell types. Further experiments
will be required to explore this possibility using a panel of
primary human cell types.
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